VERV and LLY Related Headlines
Go Back- Lilly completes Verve Therapeutics acquisition for cardiovascular treatments
- Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
- Lilly tender offer for Verve expires with 55.7% of shares tendered
- Lilly and Verve announce expiration of Verve tender offer
- Prime Medicine stock soars amid gene editing sector momentum
- BMO Capital Downgrades Verve Therapeutics (VERV) to Market Perform
VERV and LLY Related Press Releases
Go Back- Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
- Lilly and Verve announce expiration of Verve tender offer
